189 related articles for article (PubMed ID: 24055900)
1. Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab.
Chu HS; Chen TC; Hu FR; Chen WL
Cornea; 2013 Nov; 32(11):1446-53. PubMed ID: 24055900
[TBL] [Abstract][Full Text] [Related]
2. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
Chu HS; Hu FR; Yang CM; Yeh PT; Chen YM; Hou YC; Chen WL
Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
[TBL] [Abstract][Full Text] [Related]
3. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
Oh JY; Kim MK; Wee WR
Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
[TBL] [Abstract][Full Text] [Related]
4. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
[TBL] [Abstract][Full Text] [Related]
5. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
Qian CX; Bahar I; Levinger E; Rootman D
Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
You IC; Kang IS; Lee SH; Yoon KC
Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
[TBL] [Abstract][Full Text] [Related]
7. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
[TBL] [Abstract][Full Text] [Related]
8. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR
Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
Kim EK; Kong SJ; Chung SK
Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
[TBL] [Abstract][Full Text] [Related]
10. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
Benayoun Y; Adenis JP; Casse G; Forte R; Robert PY
Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
[TBL] [Abstract][Full Text] [Related]
11. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
12. [Subconjunctival bevacizumab for corneal neovascularization].
Gueudry J; Richez F; Tougeron-Brousseau B; Genevois O; Muraine M
J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
[TBL] [Abstract][Full Text] [Related]
13. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
[TBL] [Abstract][Full Text] [Related]
14. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.
Jeong JH; Chun YS; Kim ES; Kim JC
Cornea; 2011 Oct; 30(10):1071-7. PubMed ID: 21775887
[TBL] [Abstract][Full Text] [Related]
15. Combined scraping, coagulation, and subconjunctival bevacizumab in Descemet stripping automated endothelial keratoplasty for bullous keratopathy.
Chiang CC; Lin JM; Tsai YY
Eur J Ophthalmol; 2013; 23(3):309-15. PubMed ID: 23161181
[TBL] [Abstract][Full Text] [Related]
16. [Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy].
Hamdan J; Boulze M; Aziz A; Alessi G; Hoffart L
J Fr Ophtalmol; 2015 Dec; 38(10):924-33. PubMed ID: 26522892
[TBL] [Abstract][Full Text] [Related]
17. Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse.
Georgakopoulos CD; Vasilakis P; Makri OE; Beredima E; Pharmakakis N
Cutan Ocul Toxicol; 2011 Dec; 30(4):320-2. PubMed ID: 21517719
[TBL] [Abstract][Full Text] [Related]
18. Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.
Dekaris I; Gabrić N; Drača N; Pauk-Gulić M; Miličić N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):287-94. PubMed ID: 25398659
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
20. Subconjunctival bevacizumab for corneal neovascularization.
Erdurmus M; Totan Y
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
